Badanie platformowe fazy 1b/2 dotyczące wybranych skojarzeń immunoterapii u pacjentów z zaawansowanym niedrobnokomórkowym rakiem płuc (NSCLC)
Wieloośrodkowe, otwarte badanie platformowe fazy 1b/2, dotyczące wybranych skojarzeń immunoterapii u dorosłych pacjentów z wcześniej nieleczonym zaawansowanym niedrobnokomórkowym rakiem płuc (NSCLC) z wysoką ekspresją PD-L1
This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Albury, Australia, 2640
- Border Medical Oncology Research Unit
-
Bedford Park, Australia, 5042
- Flinders Medical Centre
-
St Albans, Australia, 3021
- Sunshine Hospital
-
Traralgon, Australia, 3844
- Latrobe Regional Health
-
-
-
-
-
Sankt Pölten, Austria, 3100
- Universitatsklinikum St. Poelten
-
Vienna, Austria, 1090
- Medical University of Vienna - Akh
-
-
-
-
-
Hasselt, Belgia, 3500
- Jessa Ziekenhuis
-
-
-
-
-
Barretos, Brazylia, 14784-400
- Hospital de Amor - Barretos
-
Chapecó, Brazylia, 89812618
- Supera Oncologia
-
Curitiba, Brazylia, 80810-050
- CIONC
-
Natal, Brazylia, 59035-055
- Liga Contra O Cancer - Natal
-
Porto Alegre, Brazylia, 90020-090
- Santa Casa de Porto Alegre
-
Porto Alegre, Brazylia, 90619-900
- Hospital São Lucas Da Pucrs
-
Rio de Janeiro, Brazylia, 22250-905
- Oncoclinicas Rj
-
São Paulo, Brazylia, 01509-010
- Hospital A C Camargo
-
São Paulo, Brazylia, 03102-002
- Hospital São Camilo
-
São Paulo, Brazylia, 04538-132
- Oncoclinicas Sp
-
São Paulo, Brazylia, 05652-900
- Hospital Albert Einstein
-
-
-
-
-
Dijon, Francja, 21079
- Centre Georges Francois Leclerc
-
Grenoble, Francja, 38043
- Chu Grenoble Alpes
-
Marseille, Francja, 13009
- Institut Paoli Calmette
-
Saint-Herblain, Francja, 44805
- Centre René Gauducheau/Inst de Cancér. de L'Ouest
-
Villejuif, Francja, 94805
- Institut Gustave Roussy
-
-
-
-
-
Barcelona, Hiszpania, 08035
- Vall D' Hebron Institute of Oncology (Vhio), University Hospital
-
Madrid, Hiszpania, 28007
- Hospital General Universitario Gregorio Marañón
-
Madrid, Hiszpania, 28027
- Clinica Universitaria de Navarra (Madrid)
-
Madrid, Hiszpania, 28050
- Hospital Univ. Hm Sanchinarro Start Ciocc Early Phase
-
Málaga, Hiszpania, 29010
- Hospital Universitario Virgen de La Victoria
-
Valencia, Hiszpania, 46026
- Hospital Universitario Y Politecnico La Fe
-
-
-
-
-
Hong Kong, Hongkong
- Queen Mary Hospital
-
-
-
-
-
Cluj-Napoca, Rumunia
- Inst Oncologic "Prof Dr I Chiricuta" Cluj Napoca
-
-
-
-
Michigan
-
Detroit, Michigan, Stany Zjednoczone, 48202
- Henry Ford Health
-
-
Ohio
-
Canton, Ohio, Stany Zjednoczone, 44718
- Gabrail Cancer Center
-
Columbus, Ohio, Stany Zjednoczone, 43210
- Ohio State University Comprehensive Cancer Center
-
-
-
-
-
Taipei, Tajwan, 100225
- National Taiwan University Hospital
-
Taipei, Tajwan, 114202
- Tri-Service General Hospital
-
-
-
-
-
Farkasgyepű, Węgry, 8582
- Farkasgyepu Tudogyogyintezet
-
Gyöngyös, Węgry, 3200
- Bugat Pal Hospital
-
Pécs, Węgry, 7624
- Pecsi Tudomanyegyetem, Klinikai Kozpont
-
-
-
-
-
Aviano, Włochy, 33081
- Centro Di Riferimento Oncologico
-
Meldola, Włochy, 47014
- Inst. Romagnolo Per Lo Studio E La Cura Dei Tumori
-
Milan, Włochy, 20162
- ASST Grande Ospedale Metropolitano Niguarda
-
Milan, Włochy, 20133
- Irccs Fondazione Istituto Nazionale Dei Tumori
-
Milan, Włochy, 20141
- Istituto Europeo Di Oncologia
-
Naples, Włochy, 80131
- Ist. Nazionale Tumori Irccs Fondazione G Pascale
-
Perugia, Włochy, 06132
- Azienda Ospedaliera S. Maria Della Misericordia
-
Roma, Włochy, 00144
- Istituto Nazionale Tumori Regina Elena
-
Rozzano, Włochy, 20089
- Istituto Clinico Humanitas I.R.C.C.S
-
-
-
-
-
London, Zjednoczone Królestwo, SW3 6JJ
- The Royal Marsden in Chelsea
-
London, Zjednoczone Królestwo, SM2 5PT
- The Royal Marsden in Sutton
-
Manchester, Zjednoczone Królestwo, M20 4BX
- The Christie Nhs Foundation Foundation Trust
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Adult patient aged ≥ 18 years
- Written informed consent
- Histologically (squamous or non-squamous) or cytologically documented locally advanced NSCLC not eligible for surgical resection and/or definitive chemoradiation, or metastatic NSCLC
- No prior systemic treatment for locally advanced or metastatic NSCLC
- High tumor cell PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] based on documented status as determined by an approved test
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Measurable disease as determined by RECIST v1.1
Exclusion Criteria:
- Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)
- Prior immune checkpoint inhibitor therapy
- Active brain metastases
- Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll
- Active, known or suspected autoimmune disease or immune deficiency
- History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients
- History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2
- History of inflammatory bowel disease or colitis ≥ grade 2
- History of hemophagocytic lymphohistiocytosis.
- Systemic chronic steroid therapy (>10mg/d prednisone or equivalent)
- Clinically significant infection, as assessed by the investigator
- Pregnant or breast-feeding (lactating) women
- Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)
- Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: S095018 (anti-TIM3 antibody) in combination with cemiplimab
Part A: Combination-therapy safety lead-in |
Via IV infusion on Day 1 of each 21-day cycle 350 mg via IV infusion on Day 1 of each 21-day cycle |
|
Eksperymentalny: S095024 (anti-CD73 antibody) in combination with cemiplimab
Part A: Combination-therapy safety lead-in |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Eksperymentalny: S095029 (anti-NKG2A antibody) in combination with cemiplimab
Part A: Combination-therapy safety lead-in |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Eksperymentalny: S095018 (anti-TIM3 antibody) RDE in combination with cemiplimab
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Eksperymentalny: S095024 (anti-CD73 antibody) RDE in combination with cemiplimab
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Eksperymentalny: S095029 (anti-NKG2A antibody) RDE in combination with cemiplimab
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Aktywny komparator: Cemiplimab (control arm)
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence and severity of dose-limiting toxicities (DLTs) during the first 2 cycles of combination treatment
Ramy czasowe: Through the end of the Cycle 2 (each cycle is 21 days)
|
Part A |
Through the end of the Cycle 2 (each cycle is 21 days)
|
|
Incidence and severity of adverse events (AEs)
Ramy czasowe: From the signed informed consent form (ICF) to 30 days after the last dose
|
Part A |
From the signed informed consent form (ICF) to 30 days after the last dose
|
|
Incidence and severity of serious adverse events (SAEs)
Ramy czasowe: From the signed ICF to 120 days after the last dose
|
Part A |
From the signed ICF to 120 days after the last dose
|
|
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
Ramy czasowe: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part A |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
|
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
Ramy czasowe: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part A |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
|
Objective Response (OR)
Ramy czasowe: Until study termination (approximately 2 years)
|
Part B: Participants who achieve complete response (CR) or partial response (PR), as per investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Until study termination (approximately 2 years)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Objective Response (OR)
Ramy czasowe: Until study termination (approximately 3 years)
|
Part A: Participants who achieve CR or PR, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
Best Overall Response (BOR)
Ramy czasowe: Until study termination (approximately 3 years)
|
Part A and B: The best response designation using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST), recorded between the date of the first dose of treatment and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. CR or PR used in the BOR requires a confirmation that is at least 4 weeks apart. |
Until study termination (approximately 3 years)
|
|
Duration of Response (DoR)
Ramy czasowe: Until study termination (approximately 3 years)
|
Part A and B: The time from the first documentation of CR or PR until the documented progressive disease (PD) or death, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
Disease Control (DC)
Ramy czasowe: Until study termination (approximately 3 years)
|
Part A and B: Participants who achieved stable disease (SD), PR, or CR (based on participant's best response), as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
6-month Durable Response (6-month DR)
Ramy czasowe: Until study termination (approximately 3 years)
|
Part A and B: Continuous CR or PR for ≥ 6 months, recorded between the date of the first dose of treatment and the date of the first objectively documented progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or the date of subsequent anti-cancer therapy, whichever occurs first. |
Until study termination (approximately 3 years)
|
|
Progression-Free Survival (PFS)
Ramy czasowe: Until study termination (approximately 3 years)
|
Part A and B: The time from the first dose to the first documented PD or death due to any cause, whichever occurs first, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
Plasma or serum concentration of S095018
Ramy czasowe: From first dose to 30 days after the last dose
|
Part A and B |
From first dose to 30 days after the last dose
|
|
Plasma or serum concentration of S095024
Ramy czasowe: From first dose to 30 days after the last dose
|
Part A and B |
From first dose to 30 days after the last dose
|
|
Plasma or serum concentration of S095029
Ramy czasowe: From first dose to 30 days after the last dose
|
Part A and B |
From first dose to 30 days after the last dose
|
|
Incidence and titer of anti-drug antibodies (ADA) directed against S095018
Ramy czasowe: From screening to 90 days after the last dose
|
Part A and B |
From screening to 90 days after the last dose
|
|
Incidence and titer of anti-drug antibodies (ADA) directed against S095024
Ramy czasowe: From screening to 90 days after the last dose
|
Part A and B |
From screening to 90 days after the last dose
|
|
Incidence and titer of anti-drug antibodies (ADA) directed against S095029
Ramy czasowe: From screening to 90 days after the last dose
|
Part A and B |
From screening to 90 days after the last dose
|
|
Incidence and severity of adverse events (AEs)
Ramy czasowe: From signed ICF to 30 days after the last dose
|
Part B |
From signed ICF to 30 days after the last dose
|
|
Incidence and severity of serious adverse events (SAEs)
Ramy czasowe: From signed ICF to 120 days after the last dose
|
Part B |
From signed ICF to 120 days after the last dose
|
|
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
Ramy czasowe: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part B |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
|
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
Ramy czasowe: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part B |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- SPLFIO-174
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
- used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
- sponsored by Servier
- with a first patient enrolled as of 1 January 2004 onwards
- for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Ramy czasowe udostępniania IPD
After Marketing Authorization in EEA or US if the study is used for the approval.
Kryteria dostępu do udostępniania IPD
Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .